// App-Quantinova.ai

e16079 : Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer (mCRPC): Effect of early docetaxel on outcomes.

Researchers

Presenter

  • Benjamin Louis Maughan

Principal Investigators

  • Daniel L. Suzman

  • Emmanuel S. Antonarakis

  • Rosa NadAlSunakshi Bassi

  • Michael Thomas Schweizer

Medical Centers

  • Johns Hopkins, Baltimore, MD

  • The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MDUniversity of Washington, Seattle, WAThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD

  • Johns Hopkins Medicine, Baltimore, MD

  • Johns Hopkins University, Baltimore, MD

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • N/A

Drug/Treatment

  • CB-7598

  • Docetaxel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved